Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2014

View Archived Issues

Alnylam and Genzyme expand collaboration for RNAi therapeutics

Idenix Pharmaceuticals reports data from phase II all-oral HCV combination regimen

GSK obtains option right to Santaris Pharma's LNA technology

Vaxart's H1N1 influenza vaccine shows promising protective immunity in phase Ib study

Cortice Biosciences begins enrollment in phase II trial of TPI-287 plus Avastin

Cancer Prevention Pharmaceuticals and Tillotts Pharma sign licensing agreement

Seattle Genetics and AbbVie expand antibody-drug conjugate collaboration

Probiodrug and VU University Medical Center to collaborate on Alzheimer's disease biomarker assays

Extended treatment phase of ZS-9 phase III trial in hyperkalemia meets endpoint

Achillion describes clinical development plan for oral HCV treatments

FDA clears BD Diagnostics' BD MAX MRSA XT Assay

GeoVax discloses preliminary topline results from phase I trial of vaccine to control HIV infections

Metabolic suppression-mediated discovery of novel antibacterial inhibitor compounds

Discovery and characterization of an orally potent anti-inflammatory kinase inhibitor

FDA grants QIDP designation to Carbavance

EMA committee recommends suspending use of Protelos/Osseor

Prosensa regains rights to drisapersen from GSK

First patient dosed in phase II trial of BMN-111 in children with achondroplasia

First subjects dosed in phase Il study of NKTR-171

FDA committee recommends approval of Northera NDA for treatment of symptomatic nOH

Complement factor B inhibitors described in recent Novartis patent

Boehringer Ingelheim describes K(Ca) 3.1 channel blockers

Roche reports development of tankyrase inhibitors

U.S. researchers divulge novel bacterial RNA polymerase inhibitors

MAP Pharmaceuticals patent discloses D2/5-HT1D receptor agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...